Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 16/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594135 | 0.92 | MKNK2 (0.47) | MKNK2MKNK1EGFREIF4ELMNA | |
| SCHEMBL3793901 | 0.92 | MKNK2 (0.48) | MKNK2MKNK1EGFREIF4ELMNA | |
| SCHEMBL3801706 | 0.89 | MKNK2 (0.51) | MKNK2MKNK1EIF4ELMNAPOLB | |
| SCHEMBL3805718 | 0.88 | EGFR (0.43) | MKNK2MKNK1EGFREIF4E | |
| SCHEMBL13434868 | 0.87 | MKNK2 (0.42) | MKNK2MKNK1EGFREIF4EPDE4A | |
| SCHEMBL3794206 | 0.87 | MKNK2 (0.56) | MKNK2MKNK1 | |
| SCHEMBL3798828 | 0.86 | MKNK1 (0.44) | MKNK2MKNK1EGFRFLT3 | |
| SCHEMBL3804308 | 0.85 | MKNK2 (0.56) | MKNK2MKNK1EIF4E | |
| SCHEMBL3800720 | 0.84 | MKNK2 (0.57) | MKNK2MKNK1EGFRLMNAPOLB | |
| SCHEMBL3794752 | 0.84 | MEN1 (0.47) | MKNK2MKNK1EGFRGAAPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | claimed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | claimed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | claimed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Boehringer Ingelheim Internationational GmbH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NEK9, TTBK1, NEK2 | MKNK2 11/4885MKNK1 14/4885EGFR 3571/4885 |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | MKNK2 21/4885MKNK1 74/4885EGFR 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.